Sulzer Medica on upward trend
This article was originally published in Clinica
Executive Summary
Sulzer Medica plans to continue the growth of last year through product developments and acquisitions. The company's "dual strategy" has been facilitated through the company's partial flotation in Switzerland and the US last summer, which raised over $500 million. It is possible that its parent company Sulzer may sell off a second share of its subsidiary, Sulzer Medica to raise additional funds.